These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11736877)

  • 1. Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.
    Edstein MD; Kocisko DA; Brewer TG; Walsh DS; Eamsila C; Charles BG
    Br J Clin Pharmacol; 2001 Dec; 52(6):663-70. PubMed ID: 11736877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects.
    Charles BG; Miller AK; Nasveld PE; Reid MG; Harris IE; Edstein MD
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2709-15. PubMed ID: 17517850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in thai soldiers receiving monthly prophylaxis.
    Edstein MD; Kocisko DA; Walsh DS; Eamsila C; Charles BG; Rieckmann KH
    Clin Infect Dis; 2003 Dec; 37(12):1654-8. PubMed ID: 14689348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.
    Walsh DS; Eamsila C; Sasiprapha T; Sangkharomya S; Khaewsathien P; Supakalin P; Tang DB; Jarasrumgsichol P; Cherdchu C; Edstein MD; Rieckmann KH; Brewer TG
    J Infect Dis; 2004 Oct; 190(8):1456-63. PubMed ID: 15378438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.
    Thakkar N; Green JA; Koh GCKW; Duparc S; Tenero D; Goyal N
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.
    Charles BG; Blomgren A; Nasveld PE; Kitchener SJ; Jensen A; Gregory RM; Robertson B; Harris IE; Reid MP; Edstein MD
    Eur J Clin Pharmacol; 2007 Mar; 63(3):271-8. PubMed ID: 17216435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
    Edstein MD; Walsh DS; Eamsila C; Sasiprapha T; Nasveld PE; Kitchener S; Rieckmann KH
    Med Trop (Mars); 2001; 61(1):56-8. PubMed ID: 11584657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients.
    Simpson JA; Agbenyega T; Barnes KI; Di Perri G; Folb P; Gomes M; Krishna S; Krudsood S; Looareesuwan S; Mansor S; McIlleron H; Miller R; Molyneux M; Mwenechanya J; Navaratnam V; Nosten F; Olliaro P; Pang L; Ribeiro I; Tembo M; van Vugt M; Ward S; Weerasuriya K; Win K; White NJ
    PLoS Med; 2006 Nov; 3(11):e444. PubMed ID: 17132053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafenoquine: the new kid on the block.
    Chen V; Daily JP
    Curr Opin Infect Dis; 2019 Oct; 32(5):407-412. PubMed ID: 31305490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
    Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
    Vélez ID; Hien TT; Green JA; Martin A; Sharma H; Rousell VM; Breton JJ; Ernest TB; Rolfe K; Taylor M; Mohamed K; Jones SW; Chau NH; Hoa NT; Duparc S; Tan LK; Goyal N
    Lancet Child Adolesc Health; 2022 Feb; 6(2):86-95. PubMed ID: 34871570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
    Elmes NJ; Nasveld PE; Kitchener SJ; Kocisko DA; Edstein MD
    Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1095-101. PubMed ID: 18541280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
    Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafenoquine: a promising new antimalarial agent.
    Crockett M; Kain KC
    Expert Opin Investig Drugs; 2007 May; 16(5):705-15. PubMed ID: 17461742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.
    Reuter SE; Upton RN; Evans AM; Navaratnam V; Olliaro PL
    J Antimicrob Chemother; 2015 Mar; 70(3):868-76. PubMed ID: 25377567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.
    Tan B; Naik H; Jang IJ; Yu KS; Kirsch LE; Shin CS; Craft JC; Fleckenstein L
    Malar J; 2009 Dec; 8():304. PubMed ID: 20021657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area.
    Dow GS; McCarthy WF; Reid M; Smith B; Tang D; Shanks GD
    Malar J; 2014 Feb; 13():49. PubMed ID: 24502679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis.
    Edstein MD; Nasveld PE; Kocisko DA; Kitchener SJ; Gatton ML; Rieckmann KH
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):226-30. PubMed ID: 16814823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria.
    Karbwang J; Na-Bangchang K; Thanavibul A; Bunnag D; Chongsuphajaisiddhi T; Harinasuta T
    Bull World Health Organ; 1994; 72(2):233-8. PubMed ID: 8205643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria.
    Batty KT; Le AT; Ilett KF; Nguyen PT; Powell SM; Nguyen CH; Truong XM; Vuong VC; Huynh VT; Tran QB; Nguyen VM; Davis TM
    Am J Trop Med Hyg; 1998 Nov; 59(5):823-7. PubMed ID: 9840605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.